Taiwan · Delayed Price · Currency is TWD Bioray Biotech Statistics
Total Valuation
Bioray Biotech has a market cap or net worth of TWD 779.57 million. The enterprise value is 676.01 million.
| Market Cap | 779.57M |
| Enterprise Value | 676.01M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioray Biotech has 29.59 million shares outstanding. The number of shares has decreased by -2.01% in one year.
| Current Share Class | 29.59M |
| Shares Outstanding | 29.59M |
| Shares Change (YoY) | -2.01% |
| Shares Change (QoQ) | -1.55% |
| Owned by Insiders (%) | 11.18% |
| Owned by Institutions (%) | n/a |
| Float | 13.95M |
Valuation Ratios
The trailing PE ratio is 25.60.
| PE Ratio | 25.60 |
| Forward PE | n/a |
| PS Ratio | 3.39 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | 24.94 |
| P/OCF Ratio | 23.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.47, with an EV/FCF ratio of 21.63.
| EV / Earnings | 22.16 |
| EV / Sales | 2.94 |
| EV / EBITDA | 11.47 |
| EV / EBIT | 19.03 |
| EV / FCF | 21.63 |
Financial Position
The company has a current ratio of 7.15, with a Debt / Equity ratio of 0.12.
| Current Ratio | 7.15 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.87 |
| Debt / FCF | 1.64 |
| Interest Coverage | 45.13 |
Financial Efficiency
Return on equity (ROE) is 7.12% and return on invested capital (ROIC) is 4.44%.
| Return on Equity (ROE) | 7.12% |
| Return on Assets (ROA) | 4.13% |
| Return on Invested Capital (ROIC) | 4.44% |
| Return on Capital Employed (ROCE) | 7.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.17 |
Taxes
In the past 12 months, Bioray Biotech has paid 7.73 million in taxes.
| Income Tax | 7.73M |
| Effective Tax Rate | 20.22% |
Stock Price Statistics
The stock price has increased by +16.88% in the last 52 weeks. The beta is 0.32, so Bioray Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +16.88% |
| 50-Day Moving Average | 25.40 |
| 200-Day Moving Average | 22.72 |
| Relative Strength Index (RSI) | 49.82 |
| Average Volume (20 Days) | 24,076 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioray Biotech had revenue of TWD 230.06 million and earned 30.50 million in profits. Earnings per share was 1.03.
| Revenue | 230.06M |
| Gross Profit | 107.59M |
| Operating Income | 35.52M |
| Pretax Income | 38.23M |
| Net Income | 30.50M |
| EBITDA | 50.86M |
| EBIT | 35.52M |
| Earnings Per Share (EPS) | 1.03 |
Balance Sheet
The company has 154.87 million in cash and 51.32 million in debt, giving a net cash position of 103.56 million or 3.50 per share.
| Cash & Cash Equivalents | 154.87M |
| Total Debt | 51.32M |
| Net Cash | 103.56M |
| Net Cash Per Share | 3.50 |
| Equity (Book Value) | 439.96M |
| Book Value Per Share | 14.87 |
| Working Capital | 253.05M |
Cash Flow
In the last 12 months, operating cash flow was 33.54 million and capital expenditures -2.28 million, giving a free cash flow of 31.26 million.
| Operating Cash Flow | 33.54M |
| Capital Expenditures | -2.28M |
| Free Cash Flow | 31.26M |
| FCF Per Share | 1.06 |
Margins
Gross margin is 46.77%, with operating and profit margins of 15.44% and 13.26%.
| Gross Margin | 46.77% |
| Operating Margin | 15.44% |
| Pretax Margin | 16.62% |
| Profit Margin | 13.26% |
| EBITDA Margin | 22.11% |
| EBIT Margin | 15.44% |
| FCF Margin | 13.59% |
Dividends & Yields
Bioray Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.01% |
| Shareholder Yield | n/a |
| Earnings Yield | 3.91% |
| FCF Yield | 4.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |